SUBSCRIBE
SUBSCRIBE
News   Policy

GlaxoSmithKline to Pay $460M to Resolve Avandia Lawsuits

July 14, 2010 | 
1 min read
Bloomberg -- GlaxoSmithKline Plc agreed to pay about $460 million to resolve a majority of lawsuits alleging the company’s Avandia diabetes drug can cause heart attacks and strokes, people familiar with the accords said.
Legal
GlaxoSmithKline
MORE ON THIS TOPIC
Pictured: (From L) Joe Ross, Camille Bedrosian, Emil Kakkis and Heather McKenzie
Rare diseases
FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent
June 24, 2025
 · 
3 min read
 · 
Heather McKenzie
Business
Navigating Funding Freezes and AI Frontiers
June 20, 2025
 · 
1 min read
 · 
Lori Ellis
A man is holding an umbrella while standing on a cliff. The umbrella is green and the man is looking up at the sky. Concept of danger and uncertainty, as the man is on the edge of a cliff
Regulatory
FDA Chief’s New Voucher Program Could Ease Biotech Investors’ Anxiety
June 18, 2025
 · 
2 min read
 · 
Annalee Armstrong
External view of the U.S. Capitol building
Drug pricing
Senate Republicans Drop Orphan Drug Exemptions From ‘One Big Beautiful Bill’
June 18, 2025
 · 
2 min read
 · 
Tristan Manalac